Atopic Dermatitis Drugs Market
Atopic Dermatitis Drugs Market Forecasts to 2030 - Global Analysis By Drug Class (Corticosteroids, Calcineurin Inhibitors, Systemic Immunosuppressants, Phosphodiesterase-4 (PDE4) Inhibitors, Antihistamines and Other Drug Classes), Severity, Formulation, Route of Administration, Application and By Geography
According to Stratistics MRC, the Global Atopic Dermatitis Drugs Market is accounted for $13.62 billion in 2023 and is expected to reach $25.48 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Atopic Dermatitis Drugs refer to pharmaceuticals used to manage the symptoms of atopic dermatitis, a chronic inflammatory skin condition characterized by itching, redness, and rash. By addressing the underlying immune system dysfunction, these drugs help in controlling the disease progression and minimizing long-term complications. By controlling the disease progression and enhancing skin barrier function, atopic dermatitis drugs empower patients to better manage their condition, leading to improved overall well-being and productivity.
According to the World Health Organization (WHO), over 900 million people were affected with skin disease in 2017, and around 80% of the skin disorders are accounted for by the five common skin disorders. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% of children and 1% to 3% of adults across the world.
Market Dynamics:
Driver:
Rising incidence of atopic dermatitis
With an increasing number of patients seeking treatment, there is a growing demand for effective pharmaceutical interventions. This surge in demand stimulates research and development efforts, leading to the introduction of innovative therapies. Moreover, the expanding patient pool creates a larger market opportunity for pharmaceutical companies, encouraging investment in drug development and marketing strategies. Consequently, the rising prevalence of atopic dermatitis directly fuels the growth of the atopic dermatitis drugs market.
Restraint:
Side effects and safety concerns
Side effects and safety concerns in atopic dermatitis drugs include immunosuppression, increased risk of infections, skin irritation, and allergic reactions. These adverse effects limit the widespread use of certain medications, impacting patient adherence and treatment outcomes. Moreover, safety issues raise regulatory scrutiny, prolonging approval processes and increasing development costs. High incidences of side effects also lead to patient dissatisfaction, reducing confidence in available treatments and hindering market growth.
Opportunity:
Rising healthcare expenditure
Rising healthcare expenditure enhances patient access to treatment options. With greater financial resources allocated to healthcare, individuals can afford expensive biologic drugs and novel therapies for atopic dermatitis. Moreover, increased healthcare spending often correlates with improved infrastructure, healthcare services, and patient education, leading to earlier diagnosis and treatment initiation. Overall, the uptrend in healthcare expenditure creates a conducive environment for market expansion and innovation in atopic dermatitis therapeutics.
Threat:
Generic competition
Generic competition in atopic dermatitis drugs arises when patents for branded medications expire, allowing generic drug manufacturers to produce and sell equivalent versions at lower prices. As a result, pharmaceutical companies face decreased profitability and reduced incentives for investing in research and development of innovative treatments. Additionally, generic competition limits patient access to newer, potentially more effective therapies, impacting overall market demand and growth.
Covid-19 Impact
The covid-19 pandemic has significantly impacted the atopic dermatitis drugs market. Lockdowns and disruptions in healthcare services have led to delays in diagnosis and treatment initiation for atopic dermatitis patients. Additionally, economic uncertainties have reduced patient affordability and access to expensive biologic drugs. Clinical trials for new treatments have also faced delays, affecting pipeline progress. Overall, the market has experienced a mix of challenges and opportunities, with long-term implications for growth and innovation.
The tablets segment is expected to be the largest during the forecast period
The tablets segment is estimated to have a lucrative growth. Atopic dermatitis, a chronic inflammatory skin condition, is often managed through oral medications in tablet form. These drugs aim to alleviate symptoms such as itching, inflammation, and rash associated with the condition. They offer systemic relief, targeting inflammation from within, which can be particularly effective for widespread or severe cases of atopic dermatitis. These tablets are part of a comprehensive approach to managing atopic dermatitis, often combined with topical treatments and lifestyle modifications.
The inflammation segment is expected to have the highest CAGR during the forecast period
The inflammation segment is anticipated to witness the highest CAGR growth during the forecast period. Atopic dermatitis, a chronic inflammatory skin condition, sees several drug interventions targeting inflammation. By modulating immune responses and reducing inflammation, they can prevent disease flare-ups and promote long-term remission. Overall, their efficacy in controlling inflammation not only relieves discomfort but also mitigates the risk of complications associated with chronic atopic dermatitis.
Region with largest share:
Asia Pacific is projected to hold the largest market share during the forecast period due to rising prevalence, increasing healthcare expenditure, and expanding awareness about the condition. Countries like Japan, China, and South Korea are key contributors to market expansion due to their large patient populations and improving access to healthcare. Additionally, partnerships between pharmaceutical companies and local healthcare providers facilitate market penetration. Overall, the Asia-Pacific Atopic Dermatitis Drugs Market is poised for continued expansion fuelled by evolving healthcare infrastructure and growing patient awareness.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period, owing to high prevalence of atopic dermatitis, sophisticated healthcare infrastructure, and significant investments in research and development. The United States dominates the market, with a significant portion of revenue attributed to biologic drugs and topical corticosteroids. Further, the region's well-established pharmaceutical industry and strong regulatory framework support the development and commercialization of innovative therapies.
Key players in the market
Some of the key players profiled in the Atopic Dermatitis Drugs Market include Sanofi, Regeneron Pharmaceuticals, Pfizer Inc., Novartis AG, Eli Lilly and Company, AbbVie Inc., Astellas Pharma Inc., LEO Pharma A/S, Galderma S.A., Johnson & Johnson, Bristol Myers Squibb, AnaptysBio Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, AstraZeneca PLC and Glenmark Pharmaceuticals.
Key Developments:
In January 2024, Pfizer and Glenmark Pharmaceuticals announced that they had collaborated to launch abrocitinib, an oral treatment for moderate-to-severe atopic dermatitis (AD) in India. Pfizer developed abrocitinib, which has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO). Glenmark and Pfizer will co-market the product under the brand names Jabryus and Cibinqo, respectively.
In January 2024, Sanofi's Dupixent (dupilumab) has been approved for use in treating moderate to severe atopic dermatitis in patients aged 12 and older in the European Union. It is also the first and only biologic medicine in India that has shown improved disease signs, symptoms, and quality of life measures for atopic dermatitis.
Drug Classes Covered:
• Corticosteroids
• Calcineurin Inhibitors
• Systemic Immunosuppressants
• Phosphodiesterase-4 (PDE4) Inhibitors
• Antihistamines
• Other Drug Classes
Severities Covered:
• Mild
• Moderate
• Severe
Formulations Covered:
• Tablets
• Lotions
• Syrups
• Sprays
• Other Formulations
Route of Administrations Covered:
• Topical Drugs
• Oral Drugs
• Injectable Drugs
Applications Covered:
• Phototherapy
• Immunomodulation
• Infection Prevention
• Skin Barrier Dysfunction
• Inflammation
• Itching
• Other Applications
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Atopic Dermatitis Drugs Market, By Drug Class
5.1 Introduction
5.2 Corticosteroids
5.3 Calcineurin Inhibitors
5.4 Systemic Immunosuppressants
5.5 Phosphodiesterase-4 (PDE4) Inhibitors
5.6 Antihistamines
5.7 Other Drug Classes
6 Global Atopic Dermatitis Drugs Market, By Severity
6.1 Introduction
6.2 Mild
6.3 Moderate
6.4 Severe
7 Global Atopic Dermatitis Drugs Market, By Formulation
7.1 Introduction
7.2 Tablets
7.3 Lotions
7.4 Syrups
7.5 Sprays
7.6 Other Formulations
8 Global Atopic Dermatitis Drugs Market, By Route of Administration
8.1 Introduction
8.2 Topical Drugs
8.3 Oral Drugs
8.4 Injectable Drugs
9 Global Atopic Dermatitis Drugs Market, By Application
9.1 Introduction
9.2 Phototherapy
9.3 Immunomodulation
9.4 Infection Prevention
9.5 Skin Barrier Dysfunction
9.6 Inflammation
9.7 Itching
9.9 Other Applications
10 Global Atopic Dermatitis Drugs Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Sanofi
12.2 Regeneron Pharmaceuticals
12.3 Pfizer Inc.
12.4 Novartis AG
12.5 Eli Lilly and Company
12.6 AbbVie Inc.
12.7 Astellas Pharma Inc.
12.8 LEO Pharma A/S
12.9 Galderma S.A.
12.10 Johnson & Johnson
12.11 Bristol Myers Squibb
12.12 AnaptysBio Inc.
12.13 Encore Dermatology Inc.
12.14 GlaxoSmithKline PLC
12.15 AstraZeneca PLC
12.16 Glenmark Pharmaceuticals
List of Tables
1 Global Atopic Dermatitis Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Atopic Dermatitis Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
3 Global Atopic Dermatitis Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
4 Global Atopic Dermatitis Drugs Market Outlook, By Calcineurin Inhibitors (2021-2030) ($MN)
5 Global Atopic Dermatitis Drugs Market Outlook, By Systemic Immunosuppressants (2021-2030) ($MN)
6 Global Atopic Dermatitis Drugs Market Outlook, By Phosphodiesterase-4 (PDE4) Inhibitors (2021-2030) ($MN)
7 Global Atopic Dermatitis Drugs Market Outlook, By Antihistamines (2021-2030) ($MN)
8 Global Atopic Dermatitis Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
9 Global Atopic Dermatitis Drugs Market Outlook, By Severity (2021-2030) ($MN)
10 Global Atopic Dermatitis Drugs Market Outlook, By Mild (2021-2030) ($MN)
11 Global Atopic Dermatitis Drugs Market Outlook, By Moderate (2021-2030) ($MN)
12 Global Atopic Dermatitis Drugs Market Outlook, By Severe (2021-2030) ($MN)
13 Global Atopic Dermatitis Drugs Market Outlook, By Formulation (2021-2030) ($MN)
14 Global Atopic Dermatitis Drugs Market Outlook, By Tablets (2021-2030) ($MN)
15 Global Atopic Dermatitis Drugs Market Outlook, By Lotions (2021-2030) ($MN)
16 Global Atopic Dermatitis Drugs Market Outlook, By Syrups (2021-2030) ($MN)
17 Global Atopic Dermatitis Drugs Market Outlook, By Sprays (2021-2030) ($MN)
18 Global Atopic Dermatitis Drugs Market Outlook, By Other Formulations (2021-2030) ($MN)
19 Global Atopic Dermatitis Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
20 Global Atopic Dermatitis Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
21 Global Atopic Dermatitis Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
22 Global Atopic Dermatitis Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
23 Global Atopic Dermatitis Drugs Market Outlook, By Application (2021-2030) ($MN)
24 Global Atopic Dermatitis Drugs Market Outlook, By Phototherapy (2021-2030) ($MN)
25 Global Atopic Dermatitis Drugs Market Outlook, By Immunomodulation (2021-2030) ($MN)
26 Global Atopic Dermatitis Drugs Market Outlook, By Infection Prevention (2021-2030) ($MN)
27 Global Atopic Dermatitis Drugs Market Outlook, By Skin Barrier Dysfunction (2021-2030) ($MN)
28 Global Atopic Dermatitis Drugs Market Outlook, By Inflammation (2021-2030) ($MN)
29 Global Atopic Dermatitis Drugs Market Outlook, By Itching (2021-2030) ($MN)
30 Global Atopic Dermatitis Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.